BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...billion in 2019, up 11% from RMB3.7 billion in 2018; its marketed products include Endostar, a recombinant endostatin...
BioCentury | Nov 10, 2014
Company News

iBio, Novici Biotech deal

...exclusive commercialization deal focused on antibodies and vaccine products to include iBio's IBIO-CFB03 . The endostatin-derived...
BioCentury | May 5, 2014
Company News

Oxford BioMedica, Sanofi deal

...towards year end. RetinoStat is a LentiVector-based gene therapy designed to deliver two anti-angiogenic genes, endostatin...
BioCentury | Apr 14, 2014
Clinical News

RetinoStat: Completed Phase I enrollment

...Business: Ophthalmic Molecular target: NA Description: LentiVector-based gene therapy designed to deliver 2 anti-angiogenic genes, endostatin...
BioCentury | Feb 24, 2014
Company News

Oxford BioMedica, Sanofi deal

...rejection in 2015. RetinoStat is a LentiVector-based gene therapy designed to deliver two anti-angiogenic genes, endostatin...
BioCentury | Feb 10, 2014
Company News

iBio, Medical University of South Carolina, University of Pittsburgh deal

...The University of Pittsburgh granted iBio an exclusive license to patents and IP for an endostatin-derived...
BioCentury | Oct 28, 2013
Clinical News

StarGen: Phase I/IIa ongoing

...approvals to resume recruitment in the trials. RetinoStat is designed to deliver 2 anti-angiogenic genes, endostatin...
BioCentury | Oct 28, 2013
Clinical News

UshStat: Phase I/IIa ongoing

...approvals to resume recruitment in the trials. RetinoStat is designed to deliver 2 anti-angiogenic genes, endostatin...
BioCentury | Oct 28, 2013
Clinical News

RetinoStat: Phase I ongoing

...approvals to resume recruitment in the trials. RetinoStat is designed to deliver 2 anti-angiogenic genes, endostatin...
...Business: Ophthalmic Molecular target: NA Description: LentiVector-based gene therapy designed to deliver 2 anti-angiogenic genes, endostatin...
BioCentury | Sep 2, 2013
Finance

Highlights of weekly biotech stock moves

...end (see B8) . Simcere develops and markets pharmaceuticals in China, including Endure recombinant human endostatin...
Items per page:
1 - 10 of 136